摘要
目的比较阿立哌唑与舒必利治疗女性分裂症阴性症状的疗效和安全性。方法对符合CCMD-3分裂症诊断标准、阴性症状评定量表(SANS)≥50分、临床总体印象量表(CGI)≥4分的120例女性分裂症患者,根据随机对照方案分别使用阿立哌唑和舒必利治疗,疗程均为8周。阿立哌唑组60例(脱落1例),口服阿立哌唑(20.4±5.2)mg/d;舒必利组60例(脱落2例),口服舒必利(608.2±108.3)mg/d。用阴性症状评定量表(SANS)、临床总体印象量表(CGI)评定疗效,用药物副反应量表(TESS)评定不良反应。结果经SANS、CGI评定,两组治疗后2周与治疗前比较在统计学上有显著性差异(P<0.05),治疗后第4周和第8周与治疗前比较在统计学上有高度显著性差异(P<0.01);两组间临床总体疗效在统计学上无显著性差异(P>0.05)。经TESS量表评定,阿立哌唑组嗜睡、恶心呕吐的发生率比舒必利组明显,舒必利组震颤、口干比阿立哌唑组明显。体重增加、月经改变和泌乳的发生率阿立哌唑组无,舒必利组为12.1%和25.9%。两组间总不良反应比较,阿立哌唑组少于舒必利组,在统计学上有显著性差异(P<0.05)。结论阿立哌唑治疗女性分裂症阴性症状有良好疗效,临床副反应小而安全。
Objective To evaluate the efficacy and the safety of aripiprazole and sulpiride in treatment of the female schizophrenia negative symptoms. Methods According to CCMD-3, SANS score equal or over 50 and CGI score equal or over 4, 120 female patients were designated as schizophrenia negative symptoms and randomly divided into two groups： 60 patients had been given aripiprazole （20. 4±0. 52 mg/d） for 8 weeks, and 60 patients had been given sulpiride （608.2±108.3 mg/d） for 8 weeks, then all patients were assessed by SANS, CGI and TESS. Results There were significant effects in all groups after two weeks treatment or longer. The total efficacy showed no significantly difference between two groups （P 〉 0.05）, aripiprazole got a good response in all target symptoms of SANS and CGI and had fewer side effects than sulpiride. Conclusions Aripiprazole is an effective treatment of the female schizophrenia negative symptoms and has less side effects.
出处
《神经疾病与精神卫生》
2008年第1期48-50,共3页
Journal of Neuroscience and Mental Health
